Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 173-178

  Huse, Jason T ^a   Wallace, Max ^b   Aldape, Kenneth D ^c   Berger, Mitchel S ^d   Bettegowda, Chetan ^e   Brat, Daniel J ^f   Cahill, Daniel P ^g   Cloughesy, Timothy ^h   Haas Kogan, Daphne A ^d   Marra, Marco ⁱ   Miller, C Ryan ^j   Nelson, Sarah J ^d   Salama, Sofie R ^k   Soffietti, Riccardo ^l   Wen, Patrick Y ^m   Yip, Stephen ⁿ   Yen, Katharine ^o   Costello, Joseph F ^d   Chang, Susan ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Accelerate Brain Cancer Cure   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UCLA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k University of California Santa Cruz   (United States)

^l UNIVERSITY OF TURIN   (Italy)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^o AGIOS PHARMACEUTICALS   (United States)

more..

Author keywords

clinical trials; genomics; low grade glioma; personalized medicine

Indexed keywords

ARTICLE; BRAIN CANCER; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL (TOPIC); GLIOMA; HUMAN; PERSONALIZED MEDICINE; TREATMENT PLANNING;

CLINICAL TRIALS; GENOMICS; LOW-GRADE GLIOMA; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING;

EID: 84893040660     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not229     Document Type: Article

References (40)

1. Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med. 2008; 359(5):492-507.
2. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24(8):1236-1245.
3. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048): 1453-1455.
4. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-722.
5. Kannan K, Inagaki A, Silber J, et al. Whole exome sequencing identified ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-1203.
6. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012;124(5):615-625.
7. Parsons DW, Jones S, Zhang X, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science (New York, N.Y.) 2008;321: 1807-1812.
8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
9. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations,and1p/19qloss distinguish oligodendrogliomas fromother cancers. J Pathol. 2012;226(1):7-16.
10. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338-1345.
11. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
12. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3): 549-556.
13. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065-3070.
14. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17(9):1124-1133.
15. Viaccoz A, Lekoubou A, Ducray F. Chemotherapy in low-grade gliomas. Curr Opin Oncol. 2012;24(6):694-701.
16. Glantz MJ, Burger PC, Herndon JE 2nd, et al. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology. 1991;41(11):1741-1744.
17. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001;3(3): 193-200.
18. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
19. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-567.
20. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):484- 488.
21. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
22. TurcanS,RohleD,GoenkaA, etal. IDH1mutationis sufficient toestablish the glioma hypermethylator phenotype. Nature. 2012;483(7390): 479-483.
23. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18(9): 2490-2501.
24. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
25. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150-4154.
26. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995;54(1):91-95.
27. Reifenberger G, Reifenberger J, Liu L, James CD,WechslerW, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994; 145(5):1175-1190.
28. BloughMD,Al-NajjarM, ChesnelongC, et al.DNAhypermethylationand 1p Loss silence NHE-1 in oligodendroglioma. Ann Neurol. 2012;71(6): 845-849.
29. Elsasser SJ, Allis CD, Lewis PW. Cancer. New epigenetic drivers of cancers. Science. 2011;331(6021):1145-1146.
30. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.
31. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6026.
32. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-4490.
33. HuseJT, Holland E,DeAngelis LM. Glioblastoma:molecularanalysisand clinical implications. Annu Rev Med. 2013;64:59-70.
34. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319-331.
35. Dias-Santagata D, LamQ,VernovskyK, et al.BRAFV600Emutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PloS One. 2011;6(3):e17948.
36. Rodriguez FJ, Lim KS, Bowers D, Eberhart CG. Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol. 2013;8:361-379.
37. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12(6):583-593.
38. Rohle D, Popovici-Muller J, Palaskas N, et al. Aninhibitor ofmutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
39. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra115.
40. Nelson SJ, Ozhinsky E, Li Y, Park I, Crane J. Strategies for rapid in vivo 1H and hyperpolarized 13C MR spectroscopic imaging. J Magn Reson. 2013;229:187-197.